PSTI Pluristem Therapeutc

$10.12
$0.00 (0.00%)

PSTI Stock Analysis Overview

What this means: Pluristem Therapeutc (PSTI) gets a very positive evaluation from InvestorsObserver's ranking system. An Overall Rank of 80 means that our comprehensive methodology rates Pluristem Therapeutc above 80% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Pluristem Therapeutc (PSTI) Analyst Forecast

Next 12 months ➝MEAN$16.10+59.09%HIGH$25.00+147.04%LOW$12.00+18.58%Current Price$10.1252-week High$13.2952-week Low$2.82
  • Last Price$10.12
  • Previous Close$10.12
  • Change $0.00
  • Open$9.60
  • Volume299,600
  • Avg. Volume (100-day)677,425
  • Market Capitalization$259M
  • Days Range $9.43 - $10.48
  • 52-week Range $2.82 - $13.29
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS-1.6
  • Earnings Date08/04/2019
  • SectorHealthcare
  • IndustryBiotechnology
  • Avg. Analyst Rec.
  • Beta0.784
  • PEG Ratio
Pluristem Therapeutics Inc is a US-based company which acts as a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The lead indications are critical limb ischemia, recovery after surgery for femoral neck fracture, and acute radiation syndrome. The company operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. Pluristem operates through the single business segment being Development of placenta-based cell therapy product.